Webinar | Beyond Taste: Multisensory Trends Driving Food Indulgence
14 August | 12 PM ET: Register Now

Mable (Neurolytic Healthcare)

Genomics based individualized care for people with neurological conditions.
2019
11-50
Oxford, Oxfordshire, United Kingdom
  • Bioanalytical Devices
  • Drug Delivery and Devices
  • Drug Discovery and Development
  • Medical Imaging and Visualization Technology
  • Personalized Medicine Technologies
  • Services (Patient care)
  • Wearables

Investment Funding

Last Funding Stage

Seed

Total Funding Amount

3.25M

Last Funding Amount

3.2M

Last Funding Date

27-07-2022

Startup Stage

Seed

Lead Investors

Y Combinator, Initialized Capital, Illumina, Creative Destruction Lab (CDL), Arkitekt Ventures

Revenue

$1M to $10M

People

Founders

About

Neurolytic Healthcare provides personalized medicine for neurological conditions. Neurolytic Healthcare collects and extracts insights from a combination of genetic and biomarker data to enhance diagnosis and help clinicians decide on optimal treatment strategies for neurological conditions. The company delivers digitally and genomically-driven medical devices to improve the current treatment of migraine and other neurological disorders, including a diagnostic support tool, pharmacogenetic test, and a mobile app for migraine event prediction.

Something missing or incorrect on this page? Help us enrich this information